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Abstract The aim of this paper was to examine whether cell-
penetrating peptides (CPPs) such as transportan 10 (TP10) or
protein transduction domain (PTD4) may improve the anti-
cancer activity of cisplatin (cPt). The complexes of TP10 or
PTD4 with cPt were used in the experiments. They were car-
ried out on two non-cancer (HEK293 (human embryonic kid-
ney) and HEL299 (human embryo lung)) and two cancer
(HeLa (human cervical cancer) and OS143B (human osteo-
sarcoma 143B)) cell lines. Both complexes were tested (MTT
assay) with respect to their anticancer or cytotoxic actions.
TAMRA (fluorescent dye)-stained preparations were visual-
ized in a fluorescence microscope. The long-term effect of
TP10 + cPt and its components on non-cancer and cancer cell
lines was observed in inverted phase contrast microscopy. In
the MTT test (cell viability assay), the complex of TP10 + cPt
produced a more potent effect on the cancer cell lines (HeLa,
OS143B) in comparison to that observed after separate treat-
ment with TP10 or cPt. At the same time, the action of the
complex and its components was rather small on non-cancer
cell lines. On the other hand, a complex of another CPP with
cPt, i.e., PTD4 + cPt, was without a significant effect on the
cancer cell line (OS143B). The images of the fluorescent mi-
croscopy showed TAMRA-TP10 or TAMRA-TP10 + cPt in
the interior of the HeLa cells. In the case of TAMRA-PTD4 or
TAMRA-PTD4 + cPt, only the first compound was found
inside the cancer cell line. In contrast, none of the tested
compounds gained access to the interior of the non-cancer
cells (HEK293, HEL299). Long-term incubation with the
TP10 + cPt (estimated by inverted phase contrast micros-
copy) lead to an enhanced action of the complex on cell
viability (decrease in the number of cells and change in
their morphology) as compared with that produced by each
single agent. With regard to the tested CPPs, only TP10
improved the anticancer activity of cisplatin if both com-
pounds were used in the form of a complex. Additionally,
the complex was relatively safe for non-cancer cells. What
is more, TP10 also produced an anticancer effect on HeLa
and OS143B cell lines.
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Efficient delivery of therapeutic molecules to cells is a great
challenge in modern medicine and pharmacology. Recently,
cell-penetrating peptides (CPPs) have received great attention
as efficient cellular delivery vectors due to their intrinsic abil-
ity to enter cells and mediate uptake of a wide range of macro-
or nanomolecular cargos. Generally, CPPs are relatively short
cationic peptides which are classified into two groups based
on their physicochemical characteristics: amphiphatic and
nonamphiphatic. Among the amphiphatic are transportans
(TPs) with transportan 10 (TP10) being the one of the most
widely explored. CPPs are associated with cargos via covalent
bonds or through non-covalent interactions. A large range of
chemical agents can be regarded as cargos, i.e., plasmids,
DNA, siRNA, proteins, peptides, lowmolecular weight drugs,
and nanoparticles.
Themechanisms bywhich CPPs are transclocated across the
biological membranes still remain unclear. It is known, howev-
er, that they involve rather an energy-independent cellular pro-
cess in which different endocytotic and non-endocytotic routes
are used. Which of them a CPP will utilize depends on many
factors, including, among others, the cargo and the cell type it
will enter (Lindgren and Langel 2011).
A large number of preclinical studies have reported on
successful delivery of therapeutic cargos by CPPs in different
kinds of diseases as, e.g., viral and bacterial infections,
cardiology, muscular dystrophy, and cancer (Copolovici
et al. 2014; Montrose et al. 2013; Mohandessi et al. 2012;
Freire et al. 2013). Additionally, CPPs have also been applied
in different kinds of gene modulation (Baoum et al. 2012;
Kanemaru et al. 2011), and some of them demonstrated anti-
tumor (delivery of siRNA into tumor cells) (Fang et al. 2013;
Xu et al. 2013) or antiviral activities (Zhang et al. 2008).
The potential role of CPPs, as carriers for different mole-
cules, including drugs is still a matter of considerable interest
(Kocić et al. 2011), particularly in cancer therapy. Their use
may improve chemotherapeutic strategies for example such as
prevention of the drug resistance evolution, increase in the
ability of recognition of cancer cells (targeted therapy), and
enhancement of the therapeutic response to the cargo. CPPs
may use as cargos anticancer chemotherapeutic drugs of small
molecular weight, including doxorubicin, methotrexate, and
paclitaxel (Rousselle et al. 2000; Lindgren et al. 2006; Stewart
et al. 2008). These results were an incentive for the research
undertaken in this study, the purpose of which was to find out
whether another anticancer drug, i.e., cisplatin, may be includ-
ed into the list of the abovementioned cargos.
Cisplatin (an old generation antitumor compound), being
on one hand highly effective in treatment of versatile solid
tumors, shows on the other severe toxicity which is a principle
factor that limits its usage in clinical oncology. These limita-
tions have motivated an extensive research effort towards de-
velopment of new strategies for improving platinum therapy.
One of them was introduction on the pharmaceutical market
two less toxic derivatives of cisplatin, such as carboplatin and
oxaliplatin. Nevertheless, its safety profile has not been satis-
factory. Recently, new nanotechnology has been employed
which includes among others nanocarriers for delivery of
platin compounds (Oberoi et al. 2013).
Another approach to the issue of diminishing cisplatin’s
toxicity is presented in this study. Namely, two CPPs with
cisplatin were investigated. The chosen CPPs were TP10
(one of the transportans) and protein transduction domain
(PTD4) because they fulfilled mostly the assumed criteria
(chemical structure, intracellular cleavage, antitumor activity,
lack of inhibition of GTP activity, and former experience at
this laboratory) (Ruczyński et al. 2002). Therefore, it was
interesting to find out whether the tested CPPs in the form of
non-covalent complexes with cisplatin (cPt) increase the anti-
cancer action of this drug.
Materials and Methods
Synthesis of TP10, PTD4, and their alkyne functionalized
analogs [Lys7(Prop)]TP10 and Prop-PTD4
All peptides (Table 1) were synthesized by a solid phase pep-
tide synthesis (SPPS) with the use of a Labortec AGmodel SP
486 Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:485–497
650 peptide synthesizer and Fmoc strategy (Chan and White
2000; Ruczyński et al. 2002). TentaGel S RAM resin (capac-
ity 0.25 mmol/g) was used as the starting material. All amino
acids were coupled as active derivatives in a threefold molar
excess with the use of the TBTU with addition of HOBt (1:1)
in the DMF/NMP solution. Deprotection of the Fmoc group
was carried out with 20 % piperidine in DMF. In case of TP10
analog, a hydrazine-labile ivDde group was used to protect the
ε-amino function group of Lys7 residue instead of the standard
acid-labile Boc group. As hydrazine removes the Fmoc group,
the N-terminal Ala residue was protected by the Boc group.
After completion of the peptide backbone synthesis, the ivDde
group was removed with 10 % hydrazine monohydrate in
DMF. The alkyne group (Prop) was attached to the ε-amino
function group of Lys7 residue (in case of [Lys7(Prop)]TP10)
or the N-terminal amino group (in case of Prop-PTD4) with
the use of a 10-fold molar excess of propiolic anhydride.
Peptides were cleaved from resins with TFA/phenol/TIPS/wa-
ter (88:5:2:5) mixture, and this process lasted for 2 h. Next,
crude peptides were purified and analyzed with the use of RP-
HPLC, and finally characterized by MALDI-TOF mass
spectrometry.
Synthesis of TAMRA-PEG3-N3
TAMRA-PEG3-N3 was synthesized in DCM/DMF solution
(Cunningham et al. 2010). 6-carboxytetramethylrhodamine
(TAMRA) was coupled to 1-amine-11-azido-3,6,9-
trioxoundecan (N3-PEG3-NH2) using HATU with addition
of DIPEA inDCM solution. The final product was lyophilized
and purified. Next, it was analyzed with the use of RP-HPLC,
and characterized by MALDI-TOF mass spectrometry.
Synthesis of [Lys7(C(O)-Tra(1,4)-PEG3-TAMRA)]TP10
and TAMRA-PEG3-Tra(1,4)-C(O)-PTD4 with the use
of Bclick chemistry^
The TAMRA labeled TP10 and PTD4 peptides, [Lys7(C(O)-
Tra(1,4)-PEG3-TAMRA)]TP10 and TAMRA-PEG3-Tra(1,4)-
C(O)-PTD4, were obtained with the use of Bclick
chemistry^—a specific 1,3 dipolar Huisgen cycloaddition reac-
tion (Colombo and Peretto 2008). The reaction of TAMRA-
PEG3-N3 with [Lys
7(Prop)]TP10 or Prop-PTD4 was carried
out in water/tert-butanol medium in the presence of sodium
ascorbate and CuSO4 as catalysts. The mixture was stirred at
room temperature for 24 h. After the 1,2,3-triazole forming
reaction had been completed, crude products were purified by
RP-HPLC and characterized by analytical RP-HPLC and
MALDI-TOF mass spectrometry.
Preparation of test samples
There were ten stock solutions: 0.1 % cisplatin (3.33 × 10−3 M)
and TP10 (10−4 M), TAMRA-TP10 (10−4 M), TP10 + cPt
(10−4 M), TAMRA-TP10 + cPt (10−4 M), PTD4 (10−4 M),
TAMRA-PTD4 (10−4 M), PTD4 + cPt (10−4 M), TAMRA-
PTD4 + cPt (10−4 M), and TAMRA (10−4 M). The solvents
were 0.9 % sodium chloride (NaCl).
The solutions of TP10 or TAMRA-TP10 + cPt (TP10 + cPt
or TAMRA-TP10 + cPt) were prepared by mixing 1 ml of
TAMRA-TP10 stock solution with 300-times diluted cisplatin
stock solution (11.1 × 10−6 M), and the final ratio of TP10/cPt
was 10:1. The solutions of PTD4 + cPt or TAMRA-PTD4 +
cPt were obtained in the same way, using PTD4 or TAMRA-
PTD4.
Cell lines and culture conditions
Two human cancer lines—HeLa (cervical cancer) and OS
143B (osteosarcoma)—as well as one of the human non-
cancer line—HEK293 (embryonic kidney)—were cultured
in DMEM medium with 4.5 g glucose/l (Sigma-Aldrich,
Germany) supplemented with 10 % fetal bovine serum
(FBS) (Sigma-Aldrich, Germany) and 1 % PEN/STREP
(Sigma-Aldrich, Germany). The second human non-cancer
line—HEL299 (lung fibroblasts)—was cultured in EMEM
medium (Sigma-Aldrich, Germany) supplemented in a similar
manner as the abovementioned one, but with addition of
200 mM L-glutamine solution (Sigma-Aldrich, Germany).
All cell lines were grown in a 5%CO2 humidified atmosphere
at 37 °C. The cell lines were obtained from the cell banks:
HeLa (ATCC), HEL299 (ECACC), HEK293 (local cell
bank), and OS 143B (local cell bank). The original lines were
checked for the presence of mycoplasma.
Table 1 Amino acid sequence of
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Cell viability assay
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] assay involved the following groups of
experiments:
1) cPt, TAMRA-TP10
The compounds were investigated at the concentrations
ranging from 0.1–40 μM on all tested cell lines after 24 h of
incubation. The aim of this experiment was to find out the
non-toxic concentrations in all cell lines.
Next, only non-toxic concentration of 1 μMwas tested after
24, 48, and 72 h of incubation and the further groups were:
– carried out on four tested cell lines: non-cancer
HEK293, HEL299 and cancer HeLa, OS143B
2) cPt, TAMRA-TP10, TAMRA-TP10 + cPt
– carried out on two tested cell lines: non-cancer
HEL299 and cancer OS143B
3) cPt, TP10, TP10 + cPt, TAMRA
4) cPt, TAMRA-PTD4, TAMRA-PTD + cPt, PTD4,
TAMRA-PTD4, TAMRA
MTTassay was based on the protocol described by Park et al.
(1987). MTT (5 mg/ml) was dissolved in PBS, sterilized by
filtration (0.22 μm Millipore® filter), and stored at 4 °C. Each
tested cell line was seeded at a density of 104 cells/well in a 96-
well plate in 100 μl of culture medium and allowed to grow for
24 h before adding cPt, TAMRA, TP10, TP10 + cPt, TAMRA-
TP10, TAMRA-TP10 + cPt and PTD4, PTD4 + cPt, TAMRA-
PTD4, and TAMRA-PTD4 + cPt. Apart from the first experi-
mental group, the abovementioned agents were only used at the
final concentration of 1μM.After treatment for 24, 48, and 72 h,
the cells werewashed twice in PBS and then 100μl of 0.5mg/ml
of MTT in serum-free medium was added into each well. The
incubation was continued for a further 3 h (time needed forMTT
to become metabolized) at 37 °C. Formazan, a product of the
former reaction, was dissolved in 100μl of acidified isopropanol,
and absorbance was measured at 570 nm using a DigiScan 340
microplate reader (Asys Hitech GmbH, Austria).
The results are presented as percentage of the control value,
i.e., in relation to the untreated cells (100 %).
Analysis of CPP ability to penetrate HEL299 and HeLa
cell membranes
The ability of penetration of TP10 and PTD4 was possible to
estimate due to their chemical binding with the orange fluo-
rescent dye—TAMRA.
The procedure of preparing fluorescent preparations
was as follows. Coverslips (∅20 mm) after washing with
concentrated HCl and rinsing with 70 % ethanol were
placed at the bottom of the 12-well plate. Cells were seed-
ed at 105 per 22 mm well (12-well plate) and left for 24 h.
Thereafter, they were washed three times in PBS and then
200 μl of DMEM without FBS was added (cells starvation)
and left for a further hour. Next, TAMRA-TP10, TAMRA-
PTD4, TAMRA-TP10 + cPt, and TAMRA-PTD4 + cPt at a
concentration of 10−6 M each were administered to the
wells and the samples were incubated for 1 h.
The next step involved visualization of the cell nuclei
(HEL299 and HeLa cells with the exception of the con-
trol—Fig. 6e, and TAMRA-PTD4—Fig. 6h) and mem-
branes (HeLa cells excluding TAMRA-PTD4—Fig. 6h).
Therefore, after washing the cells in PBS, they were treated
with PKH67—a green dye for the membranes (according
to the company protocol, Sigma-Aldrich, Germany) and
finally with HO3342 (Hoechst 3342) dye—a blue one for
the nuclei (Sigma-Aldrich, Germany), respectively. The
latter dye was used in a final concentration of 1 μM.
Then, the cells were fixed in 4 % formaldehyde solution
for 15 min (diluted from 37 % stock, Sigma-Aldrich,
Germany) and next, placed upside down on a Superfrost
glass plate (Roth, Germany). One drop of the Vectashild
mounting medium (Vector Laboratories, USA) was put be-
tween each mentioned glass plate and the coverslip. The
edges of the coverslips were glued with a nail polish. The
visualization was performed in a fluorescence microscope
(Delta Optical IB-100, Delta Optical, Poland), and the
fluorescence intensity emission for the dyes were as a fol-
lows: 562 nm—TAMRA, 352 nm—HO3342, and
502 nm—kit PKH67.
Phase contrast microscopy
HEL299, HeLa, and OS 143B cells were seeded in a cul-
ture flask and cultured until gaining 70 % confluence.
Next, the media were supplemented with cPt, TAMRA-
TP10, and TAMRA-TP10 + cPt in concentrations of
10−6 M each. The incubation was continued for 5 days,
and the supplemented medium was changed for a fresh
one every second day. Cells were observed in inverted
phase contrast microscope Delta Optical IB-100 equipped
with an optical camera HDCE-50B at ×20 objective
(Delta Optical, Poland).
Statistics
The data of MTT test were expressed as a mean of three
independent experiments conducted in triplicates for each
concentration. On this basis, standard error of measure-
ment (SEM) was calculated. The data of fluorescent
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microscopy included minimum 3-time repeated experi-
ments and those of contrast phase microscopy at least
three times. Data were analyzed by Friedman ANOVA
and Kendall Concordance using STATISTICA version
9.1 data analysis software system, and p < 0.05 was as-
sumed to be statistically significant (StatSoft, Inc., 2010,
www.statsoft.com.
Results
The effect of different concentrations of TAMRA-TP10
on non-cancer (HEK293, HEL299) and cancer
(HeLa, OS143B) cell lines
All tested cell lines were incubated with TAMRA-
TP10 at concentrations in the range of 0.1–40 μM. The
experiments were performed in order to select TAMRA-
TP10 concentration for further research. The criterion of
the selection was its lack of toxicity in each cell line
(Fig. 1).
Figure 1a, b shows the results of viability of non-
cancer (HEK293 and HEL299) and Fig. 1c, d shows can-
cer (HeLa, OS143B) cell lines after 24 h incubation with
TAMRA-TP10. As it turned out, the concentration of
1 μM was not toxic in all tested cell lines, and cell via-
bility remained at the control level (cells without any
agent). The concentrations above 1 μM (2.5–40 μM) of
TAMRA-TP10 reduced the cell number especially in the
cancer cell lines. For example, in the HeLa one, there was
a progressive concentration-dependent fall in cell viability
so that the inhibition of cell viability approached almost
100 % at the concentration of 40 μM.
This concentration of TAMRA-TP10 affected also both
healthy cell lines (about 80 % or 20 % drops of viability in
HEK293 or HEL299 lines, respectively).
The effect of different concentrations of cPt on non-cancer
(HEK293, HEL299) and cancer (HeLa, OS143B) cell lines
cPt at the concentration of 1 μM did not affect cell viability in
non-cancer cell lines (Fig. 2a, b). Considering the cancer cell
lines, there was a small, although a significant, drop of surviv-
al in the case of OS143B one (Fig. 2d).
The higher concentrations of the drug produced an evident
inhibition of cell viability in the cancer cell lines (Fig. 2c, d).
High sensitivity to this treatment showed OS143B line
(Fig. 2d) in which the decreases in cell viability started already
from the concentration of 1 μM and culminated at the one of
40 μM (ca. 80 %). On the other hand, the effect of cPt con-
centrations above 1 μM on non-cancer cell lines was much
smaller (Fig. 2a, b) and appeared particularly at the highest
concentration (about 15 or 35 %).
Analysis of the action of TAMRA-TP10 + cPt
and TP10 + cPt on non-cancer (HEK293, HEL299)
and cancer (HeLa, OS143B) cell lines
Figure 3 presents the effect of 24-, 48-, and 72-h incubation
with TAMRA-TP10 + cPt (1 μM) and its components—cPt
(1 μM) or TAMRA-TP10 (1 μM)—on HEK293 (Fig. 3a),
HEL299 (Fig. 3b), HeLa (Fig. 3d), and OS143B (Fig. 3e) cell
lines. Furthermore, this figure includes also the results obtain-
ed after treatment of two lines (HEL299—Fig. 3c and
OS143B—Fig. 3f) with the same agents, but without
TAMRA (TP10, TP10 + cPt), and with TAMRA alone.
All tested probes were compared to a sample without any
compounds, used as a negative control.
The action of TAMRA-TP10 + cPt on healthy cell viability
(Fig. 3a, b) was rather minimal and became most evident after
72 h. The changes after cPt or TAMRA-TP10 were even
smaller irrespective of the time of exposition.
The response of the cancer cell lines to the treatment with
TAMRA-TP10 + cPt. Figure 3d, e characterizes time-
Fig. 1 Viability of a HEK293, b
HEL299, c HeLa, andd OS143B
cell lines measured with MTT
assay after 24 h incubation with
TAMRA-TP10. All data represent
the mean ± SEM of five
independent experiments
conducted in triplicates.
Differences in viabilities were
statistically significant (marked
by asterisk) as compared to the
control (p < 0.05)
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progressive decreases in cell survival culminating in the final
drops of about 40 % (HeLa cells) and 50 % (OS143B cells).
All of them were statistically significant in comparison to the
controls (100 %). There was a difference in sensitivity of each
cancer line to cPt (Fig. 3d, e). A more noticeable effect oc-
curred on OS143B cells (a progressive fall with a max. of
30 % after 72 h). TAMRA-TP10 affected similarly viability
of both cancer cell types, and the falls achieved statistical
significance after 72 h (Fig. 3d and Fig. 3e).
To avoid the impact of TAMRA itself, the effect of the
compounds in question (TP10 + cPt or TP10) without the
dye was analyzed on one non-cancer (Fig. 3c) and one cancer
(Fig. 3f) line.
It turned out that their effects on both cell lines were com-
parable to those noticed after the complex with this dye or
TP10 with it (Fig. 3c, f). What is more, TAMRA dye did not
affect the viability of both cell lines (Fig. 3c, f). The lack of
cytotoxicity of this fluorescent dye is congruent with earlier
data considering its usage safety (Alford et al. 2009).
Analysis of the action of TAMRA-PTD4 + cPt
and PTD4 + cPt on non-cancer (HEL299) and cancer
(OS143B) cell lines
PTD4 + cPt (with TAMRA or without) as well as PTD4 (with
TAMRA or without) did not indicate a statistically significant
effect on the healthy cell viability (Fig. 4a). A lack of statisti-
cal significance was also observed in PTD4 + cPt (with
TAMRA or without)-treated OS143B cells (Fig. 4b). In the
case of PTD4 (with TAMRA or without), a statistically
significant effect (15 % decrease in cell viability) appeared
only after 72 h of incubation.
Localization of TAMRA-TP10, TAMRA-TP10 + cPt,
TAMRA-PTD4 and TAMRA-PTD4 + cPt in HEL299
and HeLa cells
The ability of crossing the cell membrane by the compounds
in question as well as their localization in the cell was verified
by fluorescence microscopy. HEL299 and HeLa cells were
incubated with TAMRA-TP10, TAMRA-TP10 + cPt, TAMRA-
PTD4, and TAMRA-PTD4 + cPt.
Figure 5a–d presents the picture of HEL299 cells after ex-
position to the tested compounds. As can be seen, there is no
internalization of the orange dye inside the cells. This obser-
vation may be evidence for a lack of penetrating ability
through the healthy cell membranes of both tested CPPs.
Figure 5e is a control picture of cancer HeLa cells without
any compounds. In this picture, the cell membranes are clearly
marked green for illustration of the their morphology. HeLa
cells incubated with TAMRA-TP10 are presented in the next
picture (Fig. 5f), and it shows the presence of this agent inside
the cells (orange color). Figure 5g visualizes cancer cells after
incubation with TAMRA-TP10 + cPt. Again, the orange color
is visible inside the cell. For a better visualization of the
compounds in question, the cell membranes and nuclei were
stained green or blue, respectively.
Additionally, the penetrating ability of another CPP, i.e.,
TAMRA-PTD4, was tested on HeLa cell line. This CPP, being
able to cross the cell membrane, is visible inside the cells
(Fig. 5h). On the other hand, if TAMRA-PTD4 was used in
Fig. 2 Viability of a HEK293, b HEL299, c HeLa, and d OS143B cell
lines measured with MTT assay after 24-h incubation with cPt. All data
represent the mean ± SEM of five independent experiments conducted in
triplicates. Differences in viabilities were statistically significant (marked
by asterisk) as compared to the control (p < 0.05)
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the complex with cPt (Fig. 5i), there is no internalization of the
orange dye, which suggests that PTD4 in this case lost its
penetrating ability.
Also, TAMRA alone does not penetrate the cellular mem-
brane and it is localized outside the cell (not shown).
Long-term effects of TAMRA-TP10 + cPt
Long-term effects of TAMRA-TP10 + cPt, cPt, and
TAMRA-TP10 were checked on one non-cancer cell line
(HEL299) and two cancer (HeLa, OS143B) cell lines for
5 days. The results of this experiments are presented in the
pictures bellow (Figs. 6, 7, and 8).
The first of them (Fig. 6a–d) presents results obtained after
the usage of the tested compounds on non-cancer cells. A
rather small decrease in the number of cells (without their
morphological changes) is only visible after long-term expo-
sition to TAMRA-TP10 + cPt (Fig. 6d).
Figure 7 and Fig. 8 show changes in the number and mor-
phology of the cells induced by the compounds in question in
the cancer cell lines. The most dramatic effect (complete or
almost complete killing of the cells) is noticed after treatment
with TAMRA-TP10 + cPt (Fig. 7d and Fig. 8d). Also, cPt
(Fig. 7b and Fig. 8b) as well as TAMRA-TP10 (Fig. 7c and
Fig. 8c) affect these cells with a resultant reduction of their
population, change in morphology, and loss of the connec-
tions between them.
Fig. 3 Viability of a HEK293, b HEL299, c HEL299, d HeLa, e
OS143B, and f OS143B cells measured with MTT assay after 24 h
(black), 48 h (gray), and 72 h (white) incubation with 1 μM of cPt,
TAMRA-TP10, TP10, TAMRA-TP10 + cPt, TP10 + cPt, and TAMRA.
All data represent the mean ± SEM of five independent experiments
conducted in triplicates for each compounds. Differences in viabilities
were statistically significant (marked by asterisk) as compared with
control (p < 0.05)
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Since the results obtained after the tested compounds with
TAMRA or without it are almost the same, the discussion of
the results in the next section will be carried out with the
omission of the dye presence in the given agent.
Discussion
TP10 + cPt—investigated in this study with respect to anti-
cancer activity—represents a non-covalent carrier-cargo com-
plex with a metal-affinity-based linkage. This non-covalent
strategy, except for its drawbacks, is more advantageous over
covalent conjugation with regard to its simplicity, versatility
of cargo composition, lowered concentrations needed to in-
duce biological response, and easy intracellular cleavage to
non-toxic metabolites (Lindgren et al. 2004; Durzyńska
et al. 2015).
As the presented here experiments have demonstrated, this
complex produced a more pronounced anticancer effect on
HeLa and OS143B cells in comparison with that observed after
incubation with each single compound, i.e., the transportan or
the anticancer drug. This statement could be made on the basis
of the MTT test, which has shown that TP10 + cPt reduced
progressively the number of cancer cells with a maximum be-
tween 40 and 50 % after 72 h. At the same time, cPt or TP10
applied separately produced a much smaller effect, i.e., a 10–
30 % or a 15 % reduction in cell survival, respectively.
In the light of the presented data, the following assump-
tions could be made. The fact that TP10 enhanced the effect of
cPt (if given in the form of a complex) may be a result of
interactions which may occur between TP10 and cPt. These
interactions may have a pharmacokinetic or pharmacodynam-
ic dimension.
The possible pharmacokinetic interactions may concern
cellular bioavailability. TP10 could intensify the transport of
cPt through the cellular membrane and thereby increase the
internalization of this anticancer drug. Similar observations
have been made by others with the usage of CPP conjugates
Fig. 4 Viability of a HEL299
and b OS143B cells measured
with MTT assay after 24 h
(black), 48 h (gray), and 72 h
(white) incubation with 1 μM of
cPt, TAMRA-PTD4,
TAMRA-PTD4 + cPt, PTD4,
PTD4 + cPt, and TAMRA. All data
represent the mean ± SEM of
three independent experiments
conducted in triplicates for each
compounds. Differences in
viabilities were statistically
significant (marked by asterisk)
as compared with control
(p < 0.05)
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Fig. 5 Transporting ability of TAMRA-TP10, TAMRA-TP10 + cPt,
TAMRA-PTD4, and TAMRA-PTD4 + cPt through the membrane of
HEL299 or HeLa cells and intracellular localization visible in
fluorescent microscopy (×100 objective except for i—×40). HEL299: a
TAMRA-TP10 (orange, blue dyes), b TAMRA-TP10 + cPt (orange, blue
dyes), c TAMRA-PTD4 (orange, blue dyes), and d TAMRA-PTD4 + cPt
(orange, blue dyes). HeLa: e control (green dye), f TAMRA-TP10
(orange, green, blue dyes), g TAMRA-TP10 + cPt (orange, green, blue
dyes), h TAMRA-PTD4 (orange dye) and i TAMRA-PTD4 + cPt (orange,
green, blue dyes). Figures are representatives of minimum three
independent experiments
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with such small chemotherapeutic anticancer drugs as doxo-
rubicin, methotrexate, or paclitaxel (Durzyńska et al. 2015;
Rousselle et al. 2000; Lindgren et al. 2006). All of them indi-
cated improved anticancer activity (in comparison with the
free drugs) which was attributed to a more efficacious cell
internalization. What is more, the studies have been carried
out on different cancer cell lines as MDA-MB-231 and K562
(Saar et al. 2005).
The issue of howCPPs deliver molecules to the cell is still a
matter of controversy. There is also no consensus considering
cell uptake of transportans and its derivatives. Most of the
experimental data provide evidence that their translocation
occurs via energy-independent route with the usage of versa-
tile pathways, as for example different types of endocytosis,
non-endocytic processes, like pore formation in the mem-
branes, formation of inverted micelles, membrane fusion,
and rupture (Islam et al. 2014; Choi and David 2014;
Durzyńska et al. 2015). In the case of TP10, it reaches prob-
ably the cell interior by concentration-dependent non-
endocytotic pathways, which was indicated in experiments
with the use of a single giant unilamellar vesicle. They re-
vealed continuous translocation across the lipid membrane at
the lower concentrations of TP10 and formation of pores at the
higher ones (Islam et al. 2014).
In the context of this study, it is worth stressing that among
the investigated CPPs, only TP10 was able to improve the
action of cisplatin. As the results of the MTT assay showed,
such phenomenon did not occur when another CPP, i.e., PTD4
Fig. 6 Long-term toxicity (after
5-day incubation) of the
compounds in HEL299 cells, a
untreated cells, b treated with cPt,
c treated with TAMRA-TP10, and
d treated with TAMRA-TP10 +
cPt. Figures are representatives of
minimum three independent
experiments (×20 objective)
Fig. 7 Long-term toxicity
(after 5-day incubation) of the
compounds in HeLa cells, a
untreated cells, b treated with cPt,
c treated with TAMRA-TP10 and
d treated with TAMRA-TP10 +
cPt. Figures are representatives of
minimum three independent
experiments (×20 objective)
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was used in the form of a complex with this anticancer drug.
The effect of PTD4 + cPt was even smaller than that observed
after cPt itself.
PTD4 is known for the delivery of proteins across the cellu-
lar membrane in a very efficacious way (Ho et al. 2001). Also,
the fluorescent microscopy experiment carried out in this study
indicated that TAMRA-PTD4 gained access to the intracellular
compartment. However, such an effect was not present after
incubation with TAMRA-PTD4 + cPt. Apparently, in the case
of this complex, PTD4 lost the transporting activity probably
due to alkylation of its chain by cPt. This did not happen with
the TAMRA-TP10 + cPt complex because the fluorescent dye
became visible in the interior of the cells.
The next issue to be discussed will concern the possible
pharmacodynamic interactions between TP10 and cPt which
may serve as an explanation for the enhanced anticancer ac-
tivity of TP10 + cPt. Of course, this kind of interaction as-
sumes such an activity of the CPP itself. In fact, a small anti-
cancer activity of TP10 which has been found in both cancer
cell lines (MTT assay) could be additive to the one performed
by cPt.
The anticancer activity of TP10 does not seem to be very
surprising as certain CPPs together with TP10, apart from the
ability to translocate the cargo, are known for other activities,
including the antitumor one (Reddy et al. 2004; Powers and
Hancock 2003; Leuschner and Hansel 2004). Although their
mechanism of the anticancer activity is not fully understood, it
may at least partly be due to the membrane perturbation (in-
duction of membrane leakage) and/or to binding to the intra-
cellular targets (Saar et al. 2005; Mader et al. 2005).
Considering the latter one, there is not much data available.
Among them, that provided by Mader et al. (2005), although
concerning another CPP (lactoferricin), seems to be attractive.
In this report, the site of action was attributed to the mitochon-
dria in which the abovementioned CPP triggered an apoptotic
pathway.
It was also found that TP10 and PTD4 had no impact on
cell viability in non-cancer (HEK293 and/or HEL299) cell
lines. An explanation for this experimental fact may be a dif-
ferent access of the tested compounds to healthy or cancer
cells. Such a difference in cellular access was visualized by
fluorescent microscopy, which showed a lack of internaliza-
tion of TP10 and PTD4 in the former ones. Thus, it may be
assumed that these compounds indicate a kind of selectivity to
the cancer cell lines. A similar phenomenon was reported by
Song et al. 2011 and Saar et al. 2005who also tested TP10, but
on other cell lines (non-cancer: NIH-3T3, AEC and cancer:
K562, MDA-MB-231). As the experiments performed in this
study indicated, the feature of selectivity could also be as-
cribed to TP10 + cPt.
It is not known which factors provide the specificity of
cationic peptides for the cancer cell membranes. However,
certain features of these membranes have been pointed out
as possible reasons, e.g., different membrane composition
and fluidity, more negative charge, higher transmembrane po-
tential, and increased level of acidic components on the sur-
face (Leuschner and Hansel 2004; Papo and Shai 2003). The
membranes of cancer cells—versus those of normal ones
(which consist of neutral zwitterionic phospholipids and ste-
rols)—carrying a net negative charge (due to increased ex-
pression of anionic molecules, i.e., phosphatidylserine, hepa-
ran sulfates) (Hoskin and Ramamoorthy 2008; Schweizer
2009) could electrostatically attract a CPP. Probably, such
phenomenon also occurs if TP10 is present in the environ-
ment. In this context, it appears to be understandable why this
peptide was preferentially bound to cancer cell membranes
Fig. 8 Long-term toxicity (after
5-day incubation) of the
compounds in OS143B cells, a
untreated cells, b treated with cPt,
c treated with TAMRA-TP10, and
d treated with TAMRA-TP10 +
cPt. Figures are representatives of
minimum three independent
experiments (×20 objective)
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and gained easier access to the cancer cells in comparison to
the healthy ones.
The discussed above possible pharmacokinetic and phar-
macodynamic interactions between TP10 and cPt could be
predictable to some extent taking into account the unique
properties of this transportan. These properties had also an
impact on its choice in the case of this study. Among them,
a special attention should be paid to the presence of lysine
(Lys) in the chemical structure of TP10. Its role seems to be
complex. As has been indicated, a reactive amino group at Lys
is a suitable handle to connect this CPP to such cargos as
hydrophilic macromolecules (Pooga et al. 1998), including
cPt. Furthermore, the number of Lys molecules enhances the
transportan’s amphipathicity which is an important parameter
that affects translocation of CPPs (Alves et al. 2008; Deshayes
et al. 2004; Song et al. 2011).
The last section of the discussion is devoted to the 5-
day effect of the complex (TP10 + cPt) and its individual
components on one non-cancer and two cancer cell lines.
This long-term effect has been estimated on the basis of
inverted phase contrast microscopic images. As compared
with TP10 or cPt, the most potent action on the cancer
cells has become visible if the complex was applied.
Thus, the presented here microscopic images may support
the results obtained in the MTT test as well as the con-
clusions drawn on their basis.
In summary, this study has demonstrated an improved an-
ticancer effect of TP10 + cPt complex in comparison with that
produced by cPt. This effect could result from pharmacokinet-
ic and/or pharmacodynamic interactions between the
complex’s components. Additionally, TP10 + cPt was rela-
tively safe for the non-cancer cell lines. Although, these con-
clusions have been drawn only on the basis of a qualitative
analysis, they may serve as grounds of further more detailed
research which would open new clinical prospects for this old
anticancer drug.
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